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Abstract Objective: Circulatory
shock is a life-threatening syndrome
resulting in multiorgan failure and a
high mortality rate. The aim of this
consensus is to provide support to the
bedside clinician regarding the diag-
nosis, management and monitoring of
shock. Methods: The European
Society of Intensive Care Medicine
invited 12 experts to form a Task
Force to update a previous consensus
(Antonelli et al.: Intensive Care Med
33:575–590, 2007). The same five
questions addressed in the earlier
consensus were used as the outline for
the literature search and review, with
the aim of the Task Force to produce
statements based on the available
literature and evidence. These ques-
tions were: (1) What are the
epidemiologic and pathophysiologic
features of shock in the intensive care
unit? (2) Should we monitor preload
and fluid responsiveness in shock? (3)
How and when should we monitor
stroke volume or cardiac output in
shock? (4) What markers of the
regional and microcirculation can be
monitored, and how can cellular
function be assessed in shock? (5)
What is the evidence for using
hemodynamic monitoring to direct
therapy in shock? Four types of
statements were used: definition,
recommendation, best practice and
statement of fact. Results: Forty-
four statements were made. The main
new statements include: (1) state-
ments on individualizing blood
pressure targets; (2) statements on the
assessment and prediction of fluid
responsiveness; (3) statements on the
use of echocardiography and hemo-
dynamic monitoring.
Conclusions: This consensus pro-
vides 44 statements that can be used
at the bedside to diagnose, treat and
monitor patients with shock.
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Introduction
Guidelines for the hemodynamic management of patients
with circulatory shock and their implications for manage-
ment [1] were developed in 2006 by a team of 25 experts in
the field of shock and a jury of 11 individuals representing
five critical care societies. In these guidelines, five specific
questions were addressed: (1) What are the epidemiologic
and pathophysiologic features of shock in the intensive
care unit (ICU)? (2) Should we monitor preload and fluid
responsiveness in shock? (3) How and when should we
monitor stroke volume or cardiac output in shock? (4)
What markers of the regional and microcirculation can be
monitored, and how can cellular function be assessed in
shock? (5) What is the evidence for using hemodynamic
monitoring to direct therapy in shock?
Since the publication of the 2006 guidelines [1], data
from several observational and randomized clinical trials
(RCTs) have been published that provide new evidence
for the optimal management of patients with circulatory
shock. In this paper, the term shock refers to circulatory
shock.
Consensus methodology
An international team of 12 experts in the field of shock
was invited by the European Society of Intensive Care
Medicine to form a Task Force to evaluate new evidence
and to revise the guidelines as judged appropriate. Four
types of statements were used for the consensus—state-
ments of facts, recommendations, best practice and
definitions (for example, definition of shock).
Statements of facts are used to summarize an
important topic discussed in the consensus when facts,
rather than actions, are discussed and agreed.
Indications to act or not to act on a specific issue are
written in the form of a ‘‘recommendation’’ or ‘‘best
practice statement’’. Although the formal GRADE
(Grading of Recommendations Assessment, Development
and Evaluation) system of evidence review with the
generation of evidence profiles was not conducted, in
making their recommendations the Task Force members
took into account the principles of the GRADE system.
This system classifies recommendations as strong (Level
1) or weak (Level 2) [2] based on the certainty of Task
Force members that following given recommendation will
result in more good than harm. Panelists were also aware
that strength of the GRADE system recommendation
depends on the quality of underlying evidence (certainty
in the estimates of effects), balance of benefits and harms,
costs and values and preferences of the interested parties.
When the panel judged that a specific recommendation
should be issued, but there was either no reasonable
alternative or sufficient indirect reasoning not to commit
time and resources to formal evidence review, best
practice statements were issued.
A modified Delphi approach was used to achieve con-
sensus. For each of the five questions included in the 2006
guidelines [1], five pairs of experts of the consensus group
were assigned the task of reviewing the new clinical trial
data and presenting their findings at a consensus confer-
ence. During the conference, held in Brussels in March
2014, the evidence and recommendations were reviewed
and discussed by the entire group and consensus reached.
A medical writer (Sophie Rushton-Smith) was present
at the conference in Brussels and recorded the minutes of
the discussion. These were used to complete the contri-
butions of the authors and to draft the first version of the
manuscript.
A conference call was held in August 2014. To com-
plete the process by taking into account the latest papers
published (up to 1 October 2014), members of the Task
Force communicated with each other via emails and
telephone conversations. The findings are presented in
this report. While the same five questions of 2006 were
used as the basis to search and discuss available literature,
the present report has been written without retaining the
order of the answers to the five questions of the 2006
consensus. This decision was based on the obvious
overlap between answers to the different questions and to
provide a more readable manuscript. The main differ-
ences between the 2007 report of Antonelli et al. [1] and
this consensus are summarized in Tables 1 and 2. The
statements issued in 2014 by the Task Force are sum-
marized in Tables 3, 4, 5 and 6.
Definition, pathophysiology, features
and epidemiology of shock
Definition
Shock is best defined as a life-threatening, generalized
form of acute circulatory failure associated with inade-
quate oxygen utilization by the cells. It is a state in which
the circulation is unable to deliver sufficient oxygen to
meet the demands of the tissues, resulting in cellular
dysfunction. The result is cellular dysoxia, i.e. the loss of
the physiological independence between oxygen delivery
and oxygen consumption, associated with increased lac-
tate levels. Some clinical symptoms suggest an impaired
microcirculation, including mottled skin, acrocyanosis,
slow capillary refill time and an increased central-to-toe
temperature gradient.
Pathophysiology and features of shock
Shock is a clinical state of acute circulatory failure [3]
that can result from one, or a combination, of four
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mechanisms [4]. The first of these is a decrease in venous
return due to a loss of circulating volume (i.e. due to
internal or external loss of fluids). The second is a failure
of the pump function of the heart that results from a loss
of contractility (resulting from ischemia, infarction,
myopathy, myocarditis) or a major arrhythmia (such as
ventricular tachycardia or a high degree A-V block). The
third is an obstruction due to pulmonary embolism, ten-
sion pneumothorax or cardiac tamponade. The fourth is
loss of vascular tone that results in maldistribution of
blood flow (due to sepsis, anaphylaxis or spinal injury).
The features of each of these four types of shock often
overlap, and patients admitted with one type of shock can
develop other types of shock. For example, patients hos-
pitalized with hemorrhagic shock due to trauma or with
cardiogenic shock occasionally develop septic shock [5,
6].
Epidemiology
Up to one-third of patients admitted to the ICU are in
circulatory shock [7], and early recognition of the con-
dition is vital if subsequent tissue injuries are to be
avoided. Shock can be categorized according to the
underlying cause, including septic shock, cardiogenic
shock, anaphylactic shock and shock associated with
burns, trauma and hemorrhage. In the 1,679 ICU patients
in the European Sepsis Occurrence in Acutely Ill Patients
II (SOAP II) trial, septic shock was the most frequent
cause of shock, accounting for 62 % of cases, followed by
cardiogenic shock (17 %) and hypovolemia (16 %) [8].
Septic shock is the most severe manifestation of sep-
sis, with reported case-fatality rates in the range of
40–50 %, reaching as high as 80 % [9]. Limited data are
available on the epidemiology of septic shock, particu-
larly in low-income countries [9], but the literature
suggests that its incidence is increasing [10–20]. The
reported incidence of septic shock in patients admitted to
the ICU varies between 6.3 and 14.7 % [1, 21].
Cardiogenic shock has most commonly been studied
in the setting of acute myocardial infarction; the incidence
in this population has remained fairly constant at between
6 and 9 %, over the past several decades [6, 22–25]. In a
multinational observational study of 65,119 patients
hospitalized for an acute coronary syndrome between
1999 and 2007, 4.6 % developed cardiogenic shock, and
the in-hospital case-fatality rate was 59.4 % [26].
Table 1 Main differences between the 2006 and 2014 consensus papers in terms of definition of shock, blood pressure statements and
fluid responsiveness statements
Topic ICM Antonelli 2007 ICM Cecconi 2014
Definition We recommend that shock be defined as a life-
threatening, generalized maldistribution of blood
flow resulting in failure to deliver and/or utilize
adequate amounts of oxygen, leading to tissue
dysoxia. Level 1; QoE moderate (B)
We define circulatory as a life-threatening, generalized
form of acute circulatory failure associated with
inadequate oxygen utilization by the cells. Ungraded
Blood pressure
statements
–We recommend a target blood pressure during
initial shock resuscitation of:
–For uncontrolled hemorrhage due to trauma: MAP
of 40 mmHg until bleeding is surgically controlled.
Level 1; QoE moderate (B)
–For TBI without systemic hemorrhage: MAP of
90 mmHg. Level 1; QoE low (C)
–For all other shock states: MAP [65 mmHg.
Level 1; QoE moderate (B)
–We recommend individualizing the target blood
pressure during shock resuscitation. Level 1; QoE
moderate (B)
–We recommend to initially target a MAP
of C65 mmHg. Level 1; QoE low (C)
–We suggest to tolerate a lower level of blood pressure
in patients with uncontrolled bleeding (i.e. in patients
with trauma) without severe head injury. Level 2; QoE
low (C)
–We suggest a higher MAP in septic patients with
history of hypertension and in patients that show clinical
improvement with higher blood pressure. Level 2; QoE
moderate (B)
Fluid responsiveness
statements
–We do not recommend the routine use of dynamic
measures of fluid responsiveness (including but
not limited to pulse pressure variation, aortic
flow changes, systolic pressure variation,
respiratory systolic variation test and collapse of
vena cava). Level 1; QoE high (A)
–There may be some advantage to these
measurements in highly selected patients. Level 1;
QoE moderate (B)
–We recommend using dynamic over static variables to
predict fluid responsiveness, when applicable. Level
1; QoE moderate (B)
–When the decision for fluid administration is made we
recommend to perform a fluid challenge, unless in cases
of obvious hypovolemia (such as overt bleeding in a
ruptured aneurysm). Level 1; QoE low (C)
–We recommend that even in the context of fluid-
responsive patients, fluid management should be titrated
carefully, especially in the presence of elevated
intravascular filling pressures or extravascular lung
water. Ungraded best practice
ICM, Intensive Care Medicine; QoE, Quality of experience, MAP, mean arterial pressure; TBI, traumatic brain injury
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The definition, pathophysiology, features and epidemi-
ology of shock
• We define circulatory shock as a life-threatening, general-
ized form of acute circulatory failure associated with
inadequate oxygen utilization by the cells. Definition.
• As a result, there is cellular dysoxia, associated with
increased blood lactate levels. Statement of fact.
• Shock can be associated with four underlying patterns, of
which three are associated with a low flow state (hypo-
volemic, cardiogenic, obstructive) and one is associated
with a hyperkinetic state (distributive). Statement of fact.
• Shock can be due to a combination of processes.
Statement of fact.
Diagnosis of shock
General considerations
The diagnosis of acute circulatory failure is based on a
combination of clinical, hemodynamic and biochemical
signs. The clinical signs of shock typically include
arterial hypotension (although this is not always pres-
ent), associated with signs of altered tissue perfusion,
visualized through the three ‘windows’ of the body
[27]: the peripheral window (skin that is cold, clammy
and blue, pale or discolored); the renal window
(decreased urine output: \0.5 mL/kg/h); the neurologic
window (altered mental characterized by obtundation,
disorientation and confusion). The presence of low
blood pressure should not be a prerequisite for defining
shock: compensatory mechanisms may preserve blood
pressure through vasoconstriction [28], while tissue
perfusion and oxygenation are already decreased sig-
nificantly [29].
General considerations
• Shock is typically associated with evidence of inade-
quate tissue perfusion on physical examination. The
three organs readily accessible to clinical assessment of
tissue perfusion are the:
Table 2 Main differences between the 2006 and 2014 consensus papers in terms of hemodynamic monitoring
Topic ICM Antonelli 2007 ICM Cecconi 2014
Hemodynamic
monitoring
–We do not recommend routine measurement of CO for
patients with shock. Level 1; QoE moderate (B)
–We suggest considering echocardiography or
measurement of CO for diagnosis in patients with clinical
evidence of ventricular failure and persistent shock with
adequate fluid resuscitation. Level 2 (weak); QoE moderate
(B)
–We do not recommend the routine use of the pulmonary
artery catheter for patients in shock. Level 1; QoE high (A)
–We recommend further hemodynamic assessment (such as
assessing cardiac function) to determine the type of
shock if the clinical examination does not lead to a clear
diagnosis. Ungraded best practice
–We suggest that, when further hemodynamic assessment
is needed, echocardiography is the preferred modality to
initially evaluate the type of shock as opposed to more
invasive technologies. Level 2; QoE moderate (B)
–In complex patients we suggest to additionally use
pulmonary artery catheterization or transpulmonary
thermodilution to determine the type of shock. Level 2;
QoE low (C)
–We do not recommend routine measurement of cardiac
output for patients with shock responding to the initial
therapy. Level 1; QoE low (C)
–We recommend measurements of cardiac output and
stroke volume to evaluate the response to fluids or
inotropes in patients that are not responding to initial
therapy. Level 1; QoE low (C)
–We suggest sequential evaluation of hemodynamic status
during shock. Level 1; QoE low (C)
–Echocardiography can be used for the sequential
evaluation of cardiac function in shock. Statement of fact
–We do not recommend the routine use of the pulmonary
artery catheter for patients in shock. Level 1; QoE high (A)
–We suggest pulmonary artery catheterization in patients
with refractory shock and right ventricular dysfunction.
Level 2; QoE low (C)
–We suggest the use of transpulmonary thermodilution or
pulmonary artery catheterization in patients with severe
shock especially in the case of associated acute respiratory
distress syndrome. Level 2; QoE low (C)
–We recommend that less invasive devices are used,
instead of more invasive devices, only when they have been
validated in the context of patients with shock. Ungraded
best practice
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– skin (degree of cutaneous perfusion);
– kidneys (urine output);
– brain (mental status).
Statement of fact.
• We recommend routine screening of patients at risk to
allow earlier identification of impending shock and
implementation of therapy. Recommendation. Level 1;
QoE low (C).
• We recommend frequent measurement of heart rate,
blood pressure, body temperature and physical exam-
ination variables (including signs of hypoperfusion,
urine output and mental status) in patients with a
history and with clinical findings suggestive of shock.
Best practice.
Hypotension and shock
The diagnostic accuracy of a systolic blood pressure of
\95 mmHg associated with acute blood loss was asses-
sed by Stern et al. in a systematic evaluation of physical
findings in patients with hypovolemia [30]. A random
effects model produced a sensitivity of 13 % for moderate
blood loss and 33 % for severe blood loss. The authors
therefore concluded that a systolic blood pressure of
\95 mmHg is not a sensitive measure for ruling out
moderate or significant blood loss. A decrease in cardiac
output is associated with significant vasoconstriction,
leading to decreased peripheral perfusion to maintain
arterial pressure [28]. The presence of hypotension is
generally included in the diagnosis of septic shock, but
several studies have actually shown that preserved blood
pressure can be associated with markers of inadequate
tissue perfusion, such as decreased central venous oxygen
saturation (ScvO2) and significantly increased concentra-
tions of blood lactate [31]. In addition, persistent
hypotension in patients with septic shock without
increased lactate levels may a have limited impact on
mortality [32].
The definition of circulatory shock emerging from this
consensus conference does not therefore require the pre-
sence of hypotension. Rather, the definition of shock as
‘life-threatening, generalized form of acute circulatory
failure associated with inadequate oxygen utilization by
the cells’ usually includes, but is not limited to, the pre-
sence of hypotension.
Hypotension and shock
• We recommend that the presence of arterial hypoten-
sion [defined as systolic blood pressure of\90 mmHg,
or mean arterial pressure (MAP) of \65 mmHg, or a
decrease of C40 mmHg from baseline], while com-
monly present, should not be required to define shock.
Recommendation. Level 1; QoE moderate (B).
Plasma lactate, mixed venous oxygen saturation
and central venous oxygen saturation and other
perfusion markers
In experimental models of acute circulatory failure
induced by arterial hypoxemia, low hemoglobin levels,
obstructive shock and septic shock, the onset of decreased
oxygen utilization relative to oxygen demand is charac-
terized by increasing lactate levels [33, 34] and decreased
regional and microcirculatory perfusion [35, 36]. Addi-
tionally, the results of limited clinical studies have shown
that inadequate oxygen is associated with increased lac-
tate levels [37–39].
Hyperlactatemia is indeed typically present in cases of
acute circulatory failure, indicating abnormal metabolism.
The usual cut-off value is 2 mEq/L (or mmol/L), but
lactate levels of [1.5 mmol/L in patients with septic
shock are associated with increased mortality [40].
Although generally increased lactate levels are associated
with abnormal oxidative phosphorylation and inadequate
oxygen utilization [38, 39], other mechanisms may also
increase lactate levels in the presence of adequate tissue
oxygenation [41–43].
The prognostic value of lactate levels exceeds that of
blood pressure [32, 44, 45]. While hyperlactatemia is
associated with worse outcome in any type of shock, a
correct interpretation also depends on the type of shock,
i.e. septic shock versus hemorrhagic shock [46].
From a metabolic perspective, elevations in blood
lactate concentration may be due to increased production,
a decreased clearance or a combination of the two. As
elevated plasma lactate forms part of the definition of
shock, the argument to measure it as a diagnostic marker
of shock is circular. Many studies have confirmed the
association between initial serum lactate level and mor-
tality independently of clinical signs of organ dysfunction
in patients not only with severe sepsis [47], but also those
in cardiogenic shock [48].
An early decrease in blood lactate levels may indicate
the resolution of global tissue hypoxia and has been
associated with a decreased mortality rate [49]. Two
studies proposed ‘lactate-based management’ of ICU
patients [50, 51]. Jones et al. [50] studied 300 patients, of
whom more than 80 % had septic shock, who were
treated to normalize central venous pressure (CVP) and
MAP; additional management to normalize lactate clear-
ance compared with management to normalize ScvO2 did
not result in different rates of hospital mortality. Jansen
et al. [51] showed, in patients with hyperlactatemia
([3.0 mEq/L) on ICU admission, that lactate-guided
therapy (with the aim of decreasing lactate by C20 %
every 2 h for the initial 8 h) in comparison with no lac-
tate-guided therapy (in which the treatment team had no
knowledge of lactate levels other than the admission
level) reduced hospital mortality when predefined risk
factors were adjusted (hazard ratio 0.61, 95 % confidence
1799
interval 0.43–0.87; P = 0.006). These authors demon-
strated a reduced rate of organ failure—but no reduced
mortality—in the lactate group compared with the control
group in the early observation period (between 9 and
72 h). Lactate levels between the control and lactate
groups were similar over a 3-day period. In clinical
practice, we suggest serial measurements of lactates and/
or base deficit to evaluate not only the outcome and
prognosis but also to guide therapy; lactate measurements
can be performed every 2 h in the first 8 h and every
8–12 h thereafter.
In the context of hyperlactatemia and mixed venous
oxygen saturation (SvO2), ScvO2 can provide important
information about the balance between oxygen transport
and oxygen demand. For example, in the context of septic
shock, low ScVO2 indicates an inadequacy of oxygen
transport, especially in the context of hyperlactatemia. In
patients with low ScVO2 values (\70 %), Rivers et al.
showed that early goal-directed therapy (EGDT) aimed at
increasing the ScVO2 to [70 % was associated to a better
outcome than a different protocolized treatment not using
this measurement to guide therapy [31]. In their study, the
mean baseline values of ScVO2 were 49 and 48 % for the
control and EGDT groups, respectively. Two recent
multicenter RCTs, the ProCESS and the ARISE trials,
failed to reproduce similar results. In these studies,
patients had a lower mortality and higher mean baseline
ScvO2 values (71 % for the ProCESS trial and 73 % for
ARISE trial) [52, 53] compared to the Rivers et al. study
[31]. In addition, in both the ProCESS and ARISE trials,
clinicians well trained in management of septic shock and
well aware of available resuscitation goals and techniques
treated the control groups.
In practice, a high ScvO2 value in the context of hy-
perlactatemia is of limited use. One of the limitations of
ScvO2 is that normal/high values cannot discriminate if
the oxygen transport is adequate, as it may remain ‘blind’
to local hypoperfusion.
The venoarterial carbon dioxide difference (pCO2
gap), which measures the difference in the partial pressure
Table 3 Summary of the consensus statements—part 1
No. Statement/recommendation GRADEa level of
recommendation;
quality of evidence
Type of
statement
1 We define circulatory as a life-threatening, generalized form of acute
circulatory failure associated with inadequate oxygen utilization by the
cells
Ungraded Definition
2 As a result, there is cellular dysoxia, associated with increased blood
lactate levels
Ungraded Statement of fact
3. Shock can be associated with four underlying patterns: three associated
with a low flow state (hypovolemic, cardiogenic, obstructive) and one
associated with a hyperkinetic state (distributive)
Ungraded Statement of fact
4. Shock can be due to a combination of processes Ungraded Statement of fact
5. Shock is typically associated with evidence of inadequate tissue
perfusion on physical examination. The three organs readily accessible
to clinical assessment of tissue perfusion are the:
-skin (degree of cutaneous perfusion);
kidneys (urine output); and
brain (mental status)
Ungraded Statement of fact
6. We recommend frequent measurement of heart rate, blood pressure,
body temperature and physical examination variables (including signs
of hypoperfusion, urine output and mental status) in patients with a
history and clinical findings suggestive of shock
Ungraded Best practice
7. We recommend not to use a single variable (for the diagnosis and/or
management of shock
Ungraded Best practice
8. We recommend efforts to identify the type of shock to better target
causal and supportive therapies
Ungraded Best practice
9. We recommend that the presence of arterial hypotension (defined as
systolic blood pressure of \90 mmHg, or MAP of \65 mmHg, or
decrease of C40 mmHg from baseline), while commonly present,
should not be required to define shock
Level 1; QoE moderate (B) Recommendation
10. We recommend routine screening of patients at risk, to allow earlier
identification of impending shock and implementation of therapy
Level 1; QoE low (C) Recommendation
11. We recommend measuring blood lactate levels in all cases where shock
is suspected
Level 1; QoE low (C) Recommendation
12. Lactate levels are typically [2 mEq/L (or mmol/L) in shock states Ungraded Statement of fact
Statements in this table are related to the initial diagnosis and recognition of shock. These are also presented in the main text together with
the rationale. The order of presentation in the table has been changed from that in the main text to allow for better reading in the table
a GRADE refers to the Grading of Recommendations Assessment, Development and Evaluation system of evidence review
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of carbon dioxide (pCO2) between mixed or central
venous blood and arterial blood, is a marker that can be
used to identify patients who are under-resuscitated.
Values of[6 mmHg suggest an insufficient blood flow in
the tissues even when the ScvO2 is [70 % [54, 55].
Although all shock states are associated with systemic
inflammation either early or later in the course of circu-
latory failure, and markers of systemic inflammation have
been associated with mortality in such cases, the levels of
these mediators are generally higher in septic patients [56–
59]. However, even in patients with septic shock, lactate
levels have a better prognostic value than other markers
[60]. There is a lack of evidence that other biomarkers of
an early hyper-inflammatory response (e.g. interleukin-1
receptor agonist, intercellular adhesion molecule 1, tumor
necrosis factor-a, caspase 3 and interleukin-8) predict
early complications, particularly in septic shock [61].
Good animal and human data are available on the role
of mediators in the evolution of shock, but current out-
come data do not support the routine use of these
mediators as biomarkers in the diagnosis and staging of
shock.
Plasma lactate, mixed venous oxygen saturation and
central venous oxygen saturation and other perfusion
markers
• We recommend measuring blood lactate levels in all
cases where shock is suspected. Recommendation.
Level 1; QoE low (C).
• Lactate levels are typically [2 mEq/L (or mmol/L) in
shock states. Statement of fact.
• We recommend serial measurements of blood lactate.
The rationale is to guide, monitor and assess. Recom-
mendation. Level 1; QoE low (C).
• In patients with a central venous catheter (CVC), we
suggest measurements of central venous oxygen satu-
ration (ScvO2) and venoarterial difference in PCO2 (V-
ApCO2) to help assess the underlying pattern and the
adequacy of cardiac output as well as to guide therapy.
Recommendation. Level 2; QoE moderate (B).
How and when to monitor cardiac function
and hemodynamics in shock
The three main reasons for monitoring cardiac function in
circulatory shock are for:
• Identifying the type of shock.
• Selecting the therapeutic intervention.
• Evaluating the patient’s response to therapy.
Identification of the type of shock
Identifying the main mechanism responsible for shock—
hypovolemic, cardiogenic, obstructive, or distributive [4,
Table 4 Summary of the consensus statements—part 2
No. Statement/recommendation GRADE level of
recommendation;
quality of evidence
Type of
statement
13. We recommend further hemodynamic assessment (such as assessing cardiac
function) to determine the type of shock if the clinical examination does not
lead to a clear diagnosis
Ungraded Best practice
14. We suggest that, when further hemodynamic assessment is needed,
echocardiography is the preferred modality to initially evaluate the type of
shock as opposed to more invasive technologies
Level 2; QoE moderate (B) Recommendation
15. In complex patients, we suggest to additionally use pulmonary artery
catheterization or transpulmonary thermodilution to determine the type of
shock
Level 2; QoE low (C) Recommendation
16. We recommend early treatment, including hemodynamic stabilization (with
fluids and vasopressors if needed) and treatment of the shock etiology, with
frequent reassessment of response
Ungraded Best practice
17. We recommend arterial and central venous catheter insertion in shock not
responsive to initial therapy and/or requiring vasopressor infusion
Ungraded Best practice
18. In patients with a central venous catheter, we suggest measurements of ScvO2)
and V-ApCO2 to help assess the underlying pattern and the adequacy of
cardiac output as well as to guide therapy
Level 2; QoE moderate (B) Recommendation
19. We recommend serial measurements of blood lactate to guide, monitor, and
assess
Level 1; QoE low (C) Recommendation
20. We suggest the techniques to assess regional circulation or microcirculation for
research purposes only
Level 2; QoE low (C) Recommendation
V-ApCO2, Veno-arterial partial pressure of carbon dioxide; ScvO2, central venous oxygen saturation
Statements in this table are related to the assessment of perfusion. These are also presented in the main text together with the rationale.
The order of presentation in the table has been changed from that in the main text to allow for better reading in the table
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62]––is of paramount importance. Context analysis
(trauma, infection, chest pain, etc.) and clinical evaluation
which focuses on skin perfusion and jugular vein disten-
sion usually orient diagnosis to the type of shock, but
complex situations may exist (e.g. cardiac tamponade in a
patient with trauma or septic shock in a patient with
chronic heart failure) in which a diagnosis is more diffi-
cult. Hence, additional hemodynamic measurements are
often needed to ascertain the type of shock, especially in
complex situations or in patients with comorbidities.
Distributive shock is usually characterized by an elevated
cardiac output, while the other types of shock are asso-
ciated with low cardiac output. Hypovolemic shock is
associated with low blood pressures and volumes, while
these are increased in cardiogenic shock. Obstructive
shock is associated with increased pulmonary artery
pressure and dilated right-sided cavities. Tamponade, a
form of obstructive shock, is associated with compression
of all cavities, and thus with elevated intracardiac pres-
sures but small cardiac volumes. In general,
hemodynamic variables such as CVP can be useful in
identifying the type of shock. However, unless in the
extreme ranges of the variables (such as a CVP of
0 mmHg in the case of a history of bleeding), they should
always be interpreted together with other variables.
Evaluation of cardiac output, cardiac function and
preload is essential when attempting to identify the type
of shock and can be obtained using various techniques.
Echocardiography allows rapid characterization of the
type of shock and is now proposed as the first-line eval-
uation modality [4]. This information can be obtained
rapidly, usually in less than 2 min, even by physicians
with minimal training [63]. The situation may evolve
over time, however, and repeated echocardiographic
Table 5 Summary of the consensus statements—part 3
No. Statement/recommendation GRADE level of
recommendation;
quality of evidence
Type of
statement
21. We recommend individualizing the target blood pressure during shock
resuscitation
Level 1; QoE moderate (B) Recommendation
22. We recommend to initially target a MAP of C65 mmHg Level 1; QoE low (C) Recommendation
23. We suggest to tolerate a lower level of blood pressure in patients with
uncontrolled bleeding (i.e. in patients with trauma) without severe head
injury
Level 2; QoE low(C) Recommendation
24. We suggest a higher MAP in septic patients with history of hypertension and in
patients that show clinical improvement with higher blood pressure
Level 2; QoE moderate (B) Recommendation
25. Optimal fluid management does improve patient outcome; hypovolemia and
hypervolemia are harmful
Ungraded Statement of fact
26. We recommend to assess volume status and volume responsiveness Ungraded Best practice
27 We recommend that immediate fluid resuscitation should be started in shock
states associated with very low values of commonly used preload parameters
Ungraded Best practice
28. We recommend that commonly used preload measures (such as CVP or PAOP
or end diastolic area or global end diastolic volume) alone should not be used
to guide fluid resuscitation
Level 1; QoE moderate (B) Recommendation
29. We recommend not to target any absolute value of ventricular filling pressure
or volume
Level 1; QoE moderate (B) Recommendation
30. We recommend that fluid resuscitation should be guided by more than one
single hemodynamic variable
Ungraded Best practice
31. We recommend using dynamic over static variables to predict fluid
responsiveness, when applicable
Level 1; QoE moderate (B) Recommendation
32. When the decision for fluid administration is made we recommend to perform a
fluid challenge, unless in cases of obvious hypovolemia (such as overt
bleeding in a ruptured aneurysm)
Level 1; QoE low (C) Recommendation
33. We recommend that even in the context of fluid-responsive patients, fluid
management should be titrated carefully, especially in the presence of
elevated intravascular filling pressures or extravascular lung water
Ungraded Best practice
34. We suggest that inotropic agents should be added when the altered cardiac
function is accompanied by a low or inadequate cardiac output, and signs of
tissue hypoperfusion persist after preload optimization
Level 2; QoE low (C) Recommendation
35. We recommend not to give inotropes for isolated impaired cardiac function Level 1; QoE moderate (B) Recommendation
36. We do not recommend targeting absolute values of oxygen delivery in patients
with shock
Level 1; QoE high (A) Recommendation
CVP, Central venous pressure; PAOP, pulmonary artery occlusion pressure
Statements in this table are related to therapeutic strategies, blood pressure targets, fluid management and inotropes. These are also
presented in the main text together with the rationale. The order of presentation in the table has been changed from that in the main text to
allow for better reading in the table
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evaluations are not always feasible. Hence, a combination
of echocardiography with other technologies is often
warranted. Advanced hemodynamic monitoring may not
be needed in non-severe episodes of shock that rapidly
respond to initial therapy based on clinical evaluation and
echocardiography. In cases of severe shock and in com-
plex conditions, advanced hemodynamic monitoring is
useful for identifying the factor(s) which contrib-
ute(s) most to the hemodynamic disturbances and on
which therapy should focus. Continuous or semi-contin-
uous measurements of cardiac output and/or SvO2 are
particularly useful as these can be nurse driven.
Identification of the type of shock
• We recommend efforts to identify the type of shock to
better target causal and supportive therapies. Best
practice.
• We recommend further hemodynamic assessment (such
as assessing cardiac function) to determine the type of
shock if the clinical examination does not lead to a
clear diagnosis. Best practice.
• We suggest that, when hemodynamic assessment is
needed, echocardiography is the preferred modality to
initially evaluate the type of shock as opposed to more
invasive technologies. Recommendation. Level 2; QoE
(B).
• We recommend not to use a single variable for the
diagnosis and/or management of shock. Best Practice.
• In complex patients we suggest to additionally use
pulmonary artery catheterization or transpulmonary
thermodilution to determine the type of shock. Recom-
mendation. Level 2; QoE low (C).
Selection of the therapeutic intervention
Target for blood pressure in the management of shock
Aggressive fluid resuscitation should be avoided and
hypotension tolerated in trauma patients with penetrating
injury—until the bleeding is surgically stopped [64]. No
equivalent guidelines are available for patients with blunt
trauma. Regarding cardiogenic shock, no clinical studies
have investigated the optimal blood pressure level, and
guidelines no longer recommend a target blood pressure
[65]. Blood pressure should be individualized for all
patients. There is evidence, however, that a mean MAP of
around 65 mmHg is sufficient in most patients with septic
shock [51, 66–69], although in patients with a history of
hypertension, a higher MAP is associated with a lower
risk of acute kidney injury [70]. Therefore, clearly the
arterial blood pressure level must be individualized. Va-
sopressors may have to be used if fluid resuscitation is not
sufficient, or they may be indicated to maintain the
desired value of MAP. In-dwelling arterial catheters allow
continuous arterial blood pressure monitoring and at the
same time allow for regular blood gas analysis. This is
particularly important in patients not responding to the
initial therapy. Central venous access may be required and
preferred to peripheral venous access when patients
admitted to the ICU require vasopressor infusions [71].
Target blood pressure in circulatory shock
• We recommend individualizing the target blood
pressure during shock resuscitation. Recommendation.
Level 1; QoE moderate (B).
Table 6 Summary of the consensus statements—part 4
No. Statement/recommendation GRADE level of
recommendation;
quality of evidence
Type of
statement
37. We do not recommend routine measurement of cardiac output for patients with
shock responding to the initial therapy
Level 1; QoE low (C) Recommendation
38. We recommend measurements of cardiac output and stroke volume to evaluate
the response to fluids or inotropes in patients that are not responding to initial
therapy
Level 1; QoE low (C) Recommendation
39. We suggest sequential evaluation of hemodynamic status during shock Level 1; QoE low (C) Recommendation
40. Echocardiography can be used for the sequential evaluation of cardiac function
in shock
Ungraded Statement of fact
41. We do not recommend the routine use of the pulmonary artery catheter for
patients in shock
Level 1; QoE high (A) Recommendation
42. We suggest pulmonary artery catheterization in patients with refractory shock
and right ventricular dysfunction
Level 2; QoE low (C) Recommendation
43. We suggest the use of transpulmonary thermodilution or pulmonary artery
catheterization in patients with severe shock especially in the case of
associated acute respiratory distress syndrome
Level 2; QoE low (C) Recommendation
44. We recommend that less invasive devices are used, instead of more invasive
devices, only when they have been validated in the context of patients with
shock
Ungraded Best practice
Statements in this table are related to cardiac function and cardiac output assessment and monitoring. These are also presented in the main
text together with the rationale. The order of presentation in the table has been changed from that in the main text to allow for better
reading in the table
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• We recommend to initially target a MAP of
C65 mmHg. Recommendation. Level 1; QoE low (C).
• We suggest to tolerate a lower level of blood pressure
in patients with uncontrolled bleeding (i.e. bleeding
patients from a road traffic accident) without severe
head injury. Recommendation. Level 2; QoE low (C).
• We suggest a higher MAP in septic patients with a
history of hypertension and in patients who improve
with higher blood pressure. Recommendation. Level 2;
QoE moderate (B).
• We recommend arterial and CVC insertion in cases of
shock unresponsive to initial therapy and/or requiring
vasopressor infusion. Best practice.
Therapeutic interventions to improve perfusion
When tissue perfusion is judged inadequate, interventions
aimed at improving perfusion can be considered. Vaso-
pressors (together with fluid resuscitation) are often
needed to restore blood pressure. The question then is
how to select between the manipulation of preload (flu-
ids), inotropic stimulation and modulation of afterload to
improve flow and perfusion? Clinical examination is often
of limited value. The detection of preload responsiveness
can be achieved through the use of several different
indices [72], but the presence of preload responsiveness
does not imply that fluids can be administered safely or
that they should be administered at all. Determination of
filling pressures, measured invasively by pulmonary
artery catheter (PAC) or estimated non-invasively by
echocardiography, and measurements of extravascular
lung water with transpulmonary thermodilution provide
important information on the risks associated with fluid
administration (see ‘‘Monitoring Preload and Fluid
Responsiveness’’ for further details).
Evaluation of cardiac function is crucial when decid-
ing on whether inotropic agents have a place in the
therapy of a given patient. Cardiac function may be
altered when cardiac output is normal or even when ele-
vated, as is often the case in myocardial depression in
sepsis. In a trial involving more than 200 patients with
septic shock, Vieillard-Baron et al. [73] observed that
several patients presented a left ventricular ejection
fraction (LVEF) of close to 40 % even though their car-
diac index was higher than 3 L/min/m2. Conversely,
several patients had a low cardiac output but preserved
cardiac function—and inotropic stimulation should not be
used in these patients. In 46 patients with septic shock,
Bouferrache et al. [74] observed that echocardiographic
assessment of myocardial function and preload respon-
siveness often led to different interventions than those
guided by the resuscitation goals proposed by the Sur-
viving Sepsis Campaign (SSC) [75]. In this study, the
authors found that agreement on the indication (or
absence of indication) for inotropic administration
occurred in 34 (74 %) of the patients, but that the eval-
uation of LVEF suggested the use of inotropic agents in
11 patients for whom the SSC guidelines suggested
otherwise. The reverse situation occurred in only one
patient. These authors therefore suggested that resuscita-
tion should be guided by measurements of LVEF rather
than by the SSC criteria. These data should, however, be
interpreted with caution as no analysis of patient outcome
was performed. The study simply illustrates that LVEF
and oxygen saturation evaluate two different aspects of
the hemodynamic state, with LVEF evaluating myocar-
dial contractility and ScvO2 evaluating the adequacy of
cardiac output according to oxygen utilization. Hence,
inotropic agents should be given only when the altered
cardiac function is accompanied by a low or inadequate
cardiac output and signs of tissue hypoperfusion are
present. The aim of the therapeutic options mentioned
above is to increase oxygen delivery (DO2) to improve
tissue perfusion. It therefore needs to be emphasized that
the ultimate goal is the improvement of tissue perfusion—
not the achievement of any specific DO2 value, which
ultimately could lead to patient’s harm [76].
Therapeutic interventions to improve perfusion
• We recommend early treatment, including hemody-
namic stabilization (with fluid resuscitation and
vasopressor treatment if needed) and treatment of the
shock etiology. Best practice.
• We suggest that inotropic agents should be added when
the altered cardiac function is accompanied by a low or
inadequate cardiac output and signs of tissue hypoper-
fusion persist after preload optimization.
Recommendation. Level 2; QoE low (C).
• We recommend not to give inotropes for isolated
impaired cardiac function. Recommendation. Level 1;
QoE moderate (B).
• We recommend not to target absolute values of oxygen
delivery in patients with shock. Recommendation.
Level 1; QoE high (A).
Evaluation of response to therapy
The aim of providing hemodynamic support in cases of
acute circulatory failure is often to increase cardiac output
in order to improve tissue perfusion or decrease pul-
monary capillary pressure. What measurements should
therefore be performed to evaluate the effects of these
interventions? While the ultimate goal is resolution of the
signs of tissue hypoperfusion (e.g. oliguria, lactate levels),
these may lack sensitivity or take time to improve.
The evaluation of cardiac output and cardiac function
can be helpful in evaluating the impact of therapeutic
interventions.
How can the effect of fluids be evaluated? Fluids are
expected to improve the hemodynamic state by increasing
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stroke volume and cardiac output. Accordingly, changes
in cardiac output by at least 10–15 % (to ascertain that
these changes are not due to measurement variability) are
used to define a positive response to fluids [77]. When
cardiac output is not measured, surrogate measurements
can be used, such as changes in end-tidal CO2 in
mechanically ventilated patients [78, 79]. Alternatively,
resolution of the signs of preload dependency indicates a
positive response to fluids. Changes in arterial pressure
are unpredictable [80, 81] and depend on vascular tone
[82]. Even though pulse pressure is related to stroke
volume, changes in pulse pressure cannot reliably predict
response to fluids [81]. Of note, an increase in CVP or in
end-diastolic volume only reflects the fact that preload
was effectively manipulated, but these measurements are
not helpful in identifying patients who experience an
increase in cardiac output in response to fluid
administration.
Evaluation of the response to inotropic agents in
patients who do not respond to the initial therapy requires
assessment of cardiac function and/or measurements of
cardiac output. When present, a rise in SvO2 suggests an
increase in cardiac output, but an increase can also occur
with significant alterations in SvO2, especially when the
SvO2 is close to the normal range and/or when oxygen
consumption (VO2) concomitantly increases, which is the
typical pattern of response in shock states characterized
by VO2 dependency [83, 84]. Under these conditions,
changes in pulse pressure also do not relate to changes in
cardiac output [80].
Evaluation of response to therapy1
• We do not recommend routine measurement of cardiac
output for patients with shock responding to the initial
therapy. Recommendation. Level 1; QoE low (C).
• We recommend measurements of cardiac output and
stroke volume to evaluate the response to fluids or
inotropes in patients that are not responding to initial
therapy. Recommendation. Level 1; QoE low (C).
• We suggest sequential evaluation of hemodynamic
status during shock. Recommendation. Level 1; QoE
low (C).
Monitoring preload and fluid responsiveness
Optimal fluid management is one of the cornerstones of
hemodynamic management in shock. Both hypovolemia
and hypervolemia are harmful states, and attempts have to
be made to administer the fluids in the best possible way.
Therefore, the first questions physicians should ask
themselves are: (1) whether the clinical problem at hand
can be (partially) resolved by increasing cardiac output
and (2) whether fluid resuscitation will be effective to
achieve this target.
Preload, along with afterload and cardiac contractility,
is an important determinant of cardiac output. Preload has
been defined as myocardial stretch imposed by ventricular
filling at the end of the diastole. While fluid resuscitation
should not be delayed, efforts should be made to assess if
a patient will respond to fluids. Ideally, in cases of shock,
a clinician should be able to use a measure of preload to
determine whether a patient requires additional fluids to
increase cardiac output. CVP and pulmonary artery
occlusion pressure (PAOP) are the most commonly used
estimates of right ventricular (RV) and LV preloads,
respectively. Volumetric parameters, assessed by trans-
pulmonary thermodilution, and end-diastolic ventricular
volumes, determined by echocardiography, are also used
to evaluate preload [72]. However, each of these pressure
and volume measurements has their limitations. Dynamic
measures of assessing whether a patient requires addi-
tional fluid to increase stroke volume (i.e. assessing fluid
responsiveness) have been proposed in an effort to
improve fluid management. The principle behind dynamic
measures is that changes in intrathoracic pressure
imposed by mechanical ventilation impact on venous
return and subsequent cardiac output. During a positive
pressure breath, RV filling has been shown to decrease by
20–70 %, leading to a decrease in stroke volume that can
be amplified by an increasing degree of hypovolemia [85,
86]. This finding indicates that dynamic measures allow
the discrimination of preload-dependent and preload-
independent hemodynamic situations (i.e. these measures
identify the position of a patient’s individual Frank–
Starling curve). Different dynamic measures are currently
available and can be routinely assessed at the bedside
using standard and minimally invasive hemodynamic
monitoring systems. These include the assessment of
pulse pressure variation (PPV) and stroke volume varia-
tion (SVV) via the arterial line or non-invasively by
plethysmography, as well as of aortic flow variation and
vena cava collapsibility or distensibility determined by
Doppler and other modalities of echocardiography [87–
89]. The need for additional fluid may also be evaluated
by observing the response to a volume challenge. Fol-
lowing the rapid administration of a bolus of intravenous
fluid (i.e. 500 mL in\30 min) or a passive leg-raising test
(which is akin to a fluid load, as venous return increases),
cardiac output immediately increases in patients who are
fluid-responsive [3, 77, 90].
Despite the fact that current guidelines as well as
important clinical trials have used measures of preload to
guide fluid resuscitation, clinicians should be cautious
when using such measures. Importantly, any measure of
preload, particularly if it is a one-time measurement,
1Refers also to the statements related to ‘general considerations’
and ‘plasma lactate, mixed venous oxygen saturation and central
venous oxygen saturation and other perfusion markers’ discussed in
the section ‘‘Diagnosis of shock’’)
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should not be taken out of context with respect to the
measures of other variables and the patient’s overall
clinical condition. For example, a normal individual with
a normal vascular volume has a very low CVP and does
not require additional fluid; alternatively, some patients
with high measures of preload pressure may benefit from
additional fluids. Thus, changes in these parameters fol-
lowing interventions may be much more useful than a
single measurement. Unfortunately, poor correlations
between estimates of preload (whether pressures or vol-
umes) and predictions of fluid responsiveness have been
widely reported. For example, in normal healthy volun-
teers, both CVP and PAOP are poor predictors of preload,
cardiac performance and changes in cardiac performance
following fluid loading compared with measurements of
end-diastolic ventricular volumes. End-diastolic ventric-
ular volumes have also been found to provide superior
estimates of preload compared with CVP and PAOP in
diverse groups of critically ill patients [91]. Nonetheless,
there may be clinical settings, such as severe congestive
heart failure or hypovolemia, where titration of fluid
therapy based on CVP and PAOP may be helpful [92].
Notably, measurements of ventricular volumes are not
always easy to obtain (especially on the right side of the
heart), are associated with costs and time delays and are
operator-dependent. A number of studies have shown that
dynamic measures of fluid responsiveness are better pre-
dictors of fluid responsiveness than static parameters in
mechanically ventilated patients. PPV and SVV, for
example, have proven to be good predictors of fluid
responsiveness in sedated mechanically ventilated
patients without spontaneous breathing activities and in
sinus rhythm. Dynamic measures do have several limi-
tations, however. Importantly, patients must be on fully
controlled mechanical ventilation without spontaneous
efforts, which is seldom the case in ICU patients. In
addition, these parameters are affected by the magnitude
of the employed tidal volume. Finally, most of the eval-
uations involving dynamic measures have included
relatively stable patients, such as post-cardiac surgery
patients, and the extent to which these measures are useful
in other potentially unstable populations is uncertain. Few
studies evaluating measures of fluid responsiveness have
specifically focused on the spontaneously breathing
patient. Not surprisingly, the measurement of PPV had no
predictive value in the subgroup of patients with sponta-
neous breathing activity [93]. However, reductions in
right atrial pressures by at least 1 mmHg during a spon-
taneous inspiration have been shown to be a reasonable
predictor of fluid responsiveness [94–96]. Passive leg-
raising (e.g. 45 elevation for 4 min while maintaining the
trunk supine) results in an increase in RV and LV preload.
Such a test may help in predicting individual fluid
responsiveness during spontaneous and positive pressure
breaths while avoiding the hazards of unnecessary fluid
loading [97, 98].
Monitoring preload and fluid responsiveness
• Optimal fluid management does improve patient out-
come; hypovolemia and hypervolemia are harmful.
Statement of fact.
• We recommend to assess volume status and volume
responsiveness. Best practice.
• We recommend that immediate fluid resuscitation
should be started in shock states associated with very
low values of commonly used preload parameters. Best
practice.
• We recommend that commonly used preload measures
(such as CVP or PAOP or global end diastolic volume
or global end diastolic area) alone should not be used to
guide fluid resuscitation. Recommendation. Level 1;
QoE moderate (B).
• We recommend not to target any ventricular filling
pressure or volume. Recommendation. Level 1; QoE
moderate (B).
• We recommend that fluid resuscitation should be
guided by more than one single hemodynamic variable.
Best practice.
• We recommend using dynamic over static variables to
predict fluid responsiveness, when applicable. Recom-
mendation. Level 1; QoE moderate (B).
• When the decision for fluid administration is made, we
recommend to perform a fluid challenge, unless in
cases of obvious hypovolemia (such as overt bleeding
in a ruptured aneurysm). Recommendation, Level 1;
QoE low (C).
• We recommend that even in the context of fluid-
responsive patients, fluid management should be
titrated carefully, especially in the presence of elevated
intravascular filling pressures or extravascular lung
water. Best practice.
Monitoring cardiac function and cardiac output
Echocardiography
Echocardiography cannot provide continuous hemody-
namic data. Nevertheless, it is the best bedside method to
assess cardiac function repeatedly. Echocardiography can
help the ICU physician in three ways: (1) better charac-
terization of the hemodynamic disorders; (2) selection of
the best therapeutic options (intravenous fluids, inotropes
and ultrafiltration); (3) assessment of the response of the
hemodynamic disorders to therapy.
Doppler echocardiography provides an estimation of
stroke volume and hence cardiac output using the calcu-
lation of the velocity–time integral (VTI) of the subaortic
blood flow and the area of the duct crossed by this flow.
Since the area of the subaortic tract does not change over
time, it is sufficient to follow short-term changes in VTI
in order to assess changes in stroke volume.
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Doppler echocardiography provides measurements of
LVEF, which depends mainly on LV contractility and LV
afterload. Thus, LVEF is not a precise marker of LV
contractility but rather reflects the way the heart is able to
adapt to the actual loading conditions with its intrinsic
contractility. This is particularly important in shock
patients in whom LV afterload can change markedly over
a short period. Therefore, the LVEF must be correctly
interpreted to take into account the systolic arterial pres-
sure. Visual estimation of LVEF provides values very
close to those measured by the orthogonal plan method
[99], and this measurement can be obtained by most ICU
physicians, even those who are moderately experienced
with echocardiography [100].
LV filling pressures are best evaluated using analysis of
the transmitral flow with pulsed Doppler echocardiography
and the tissue Doppler imaging of the mitral annulus [101].
Analysis of transmitral flow allows measurement of the
peak Doppler velocities of early (E) and late diastolic flow
(A). The E/A ratio has been proposed as an estimation of
the LV filling pressure [102], but this measurement is
affected by diastolic function. Early diastolic mitral
annular velocity (E0) measured with tissue Doppler imag-
ing evaluates diastolic function in a load-independent
manner [103]. The combination of tissue Doppler imaging
and pulsed Doppler echocardiography of transmitral flow
allows calculation of the E/E0 ratio, which is considered to
be one of the best echocardiographic estimates of LV
filling pressure [103, 104]. However, echocardiography
provides only a semi-quantitative estimate of LV filling
pressures. Although an E/E0 value of\8 is a good predictor
of low LV filling pressure and an E/E0 value of [15 is a
good predictor of high LV filling pressure, a value between
8 and 15 cannot reliably predict the LV filling pressure
[105]. This is not a minor issue as most E/E0 values are
between 8 and 15 in critically ill patients [104, 106].
Echocardiography also provides dynamic parameters
of preload responsiveness through analysis of the respi-
ratory variability of VTI [88] or the inferior or superior
vena cava diameter [88, 107] or through the response of
VTI to passive leg-raising [98, 108].
Doppler echocardiography provides an estimation of
RV function through comparison of the RV end-diastolic
area (RVEDA) with the LV end-diastolic area (LVEDA).
A RVEDA/LVEDA ratio of between 0.6 and 1 suggests
the presence of moderate RV dilatation, and a ratio [1
suggests the presence of severe RV dilatation. Some
authors have defined acute cor pulmonale as the combi-
nation of a RVEDA/LVEDA ratio [0.6 and the presence
of a paradoxical septal motion [109–111].
Pulmonary artery catheter
The PAC provides the ICU physician with information on
important hemodynamic variables [e.g. right atrial
pressure, pulmonary artery pressure (PAP), PAOP and
cardiac output) and tissue perfusion variables (e.g. SvO2,
oxygen utilization, oxygen delivery, oxygen extraction
and PvCO2]. All of these variables can be useful in the
management of patients with shock.
Right atrial pressure and PAP are particularly useful
for managing patients with shock associated with RV
dysfunction and/or acute respiratory distress syndrome
(ARDS). PAOP is assumed to reflect the LV end-diastolic
pressure. Correct measurements and appropriate inter-
pretation of PAOP represent a difficult challenge,
especially in patients receiving positive end-expiratory
pressure (PEEP) [112, 113] or in the presence of intrinsic
PEEP [113], where the measured PAOP overestimates the
transmural PAOP.
Cardiac output can be measured intermittently
according to the thermodilution principle after cold bolus
injections. This is classically considered as the reference
method, although it suffers from a number of methodo-
logical limitations, such as tricuspid regurgitation. The
semi-continuous thermodilution method is based on the
intermittent and automatic heating of blood by means of a
proximal thermal filament and the recording of the tem-
perature changes using a distal thermistor. The results
obtained with continuous thermodilution agree with those
provided by the intermittent technique, except for high
values of cardiac output, which can be underestimated by
the continuous method [114]. This technique presents the
advantage of a continuous display of cardiac output and
avoids repeated manipulations of the catheters and bolus
injections. The major limitation is that it does not enable
real-time monitoring of cardiac output as it averages
several successive cardiac output measurements.
The PAC can also provide intermittent or continuous
measurements of SvO2 and intermittent measurements of
PvCO2; both variables are helpful in assessing the ade-
quacy of the cardiac output for oxygen (O2) utilization
and for the clearance of carbon dioxide (CO2) produced
by cellular metabolism.
The main limitation of the PAC is its invasiveness,
which explains in part the decline in its use during the
past decade when less invasive hemodynamic techniques
have been developed. Nevertheless, the PAC can still be
helpful for the management of shock states refractory to
the initial treatment, especially those with RV dysfunction
or with complex circulatory conditions in which the
knowledge of PAP, PAOP and oxygenation parameters is
believed to be important for identifying the main disor-
ders. Monitoring with a PAC is commonplace in the ICU
setting despite the lack of high-quality data to support its
benefits [115]. While the availability of cardiac output
and other hemodynamic variables obtained using a PAC
can improve the diagnosis and management of circulatory
instability, the device can also cause complications and
provide inaccurate measurements, and the data can be
difficult to interpret [116].
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Published evidence on the use of PACs in the ICU is
conflicting, with some early non-randomized trials sug-
gesting increased rates of mortality and morbidity and
longer hospital stays. The results of a prospective study
with propensity-matched groups showed that patients
receiving a PAC had a higher rate of 30-day death, higher
hospital costs and increased duration of ICU stay com-
pared with patients who did not receive a PAC [116].
Analysis of data from an observational study in over
4,000 patients undergoing non-cardiac surgery revealed
an increase in the rate of postoperative major cardiac and
non-cardiac complications in those who underwent peri-
operative right heart catheterization [117]. In contrast,
two recent studies, both of which used propensity scores
to account for illness severity, reported similar outcomes
in critically ill patients with or without a PAC [118, 119].
In a retrospective study of 119 consecutive patients with
ARDS, monitoring with a PAC was not an independent
predictor of death [120].
The impact of PAC on mortality and morbidity in
critically ill patients has also been reported in several,
more recent RCTs [121–124]. One study involving 201
patients reported no difference in mortality related to
PAC use, but more fluids were given in the first 24 h to
the PAC group, and the rates of acute renal failure and
thrombocytopenia 3 days after randomization were
greater in this group [121]. Similarly, in 676 patients with
shock and/or ARDS, the use of a PAC did not signifi-
cantly improve morbidity or reduce mortality [122].
Harvey et al. reported that they found no evidence of
benefit or harm with the use of a PAC in a study of 1,041
ICU patients [123]. Wheeler et al. conducted a random-
ized trial in 1,000 patients with ARDS or acute lung
injury with the aim of comparing hemodynamic man-
agement guided by PAC and by CVC [124]. These
authors reported that there were no differences in 60-day
mortality, time on the ventilator or days spent in the ICU,
but the PAC group did have a higher rate of catheter-
related complications, largely arrhythmias [124]. Shah
et al., in a meta-analysis of the efficacy and safety of the
PAC in 5,051 critically ill patients (13 RCTs) [125],
reported that the use of a PAC was not associated with an
increased rate of death or length of hospitalization, but the
results also failed to demonstrate improved survival
associated with PAC use.
Transpulmonary thermodilution devices
Transpulmonary thermodilution devices are considered to
be less invasive than the PAC, but they still require
insertion of a CVC and femoral arterial catheter. These
devices combine transpulmonary thermodilution and
pulse contour analysis.
Transpulmonary thermodilution provides intermittent
measurements of cardiac output after a cold bolus
injection into a central vein and detection of changes in
the blood temperature in the femoral artery. The tech-
nique has been compared favorably with pulmonary
thermodilution in critically ill patients, including some in
shock [126]. Transpulmonary thermodilution also pro-
vides intermittent measurements of: (1) global end-
diastolic volume, a volumetric marker of cardiac preload;
(2) cardiac function index, a marker of systolic function
of the heart; (3) extravascular lung water, a quantitative
index of pulmonary edema.
Arterial pulse wave analysis measures cardiac output
by placing sensors placed directly into the femoral artery
catheter which record the arterial pressure waveform
through the femoral artery catheter. Determination of
pulse contour cardiac output uses proprietary algorithms
based on the relationship between stroke volume and
arterial pressure waveform, which is influenced by the
resistive and elastic characteristics of the arterial system.
Intermittent transpulmonary thermodilution cardiac out-
put measurements are used to calibrate the pulse contour
cardiac output, and good agreement with thermodilution
cardiac output has been reported in hemodynamically
unstable patients [127]. However, there is a potential drift
with time, making recalibration mandatory. After a 1-h
calibration-free period, recalibration may be encouraged
in patients with septic shock who are receiving vaso-
pressors [128].
The clinical interest for such real-time cardiac output
monitoring is to improve diagnostics so that patients in
whom cardiac output is dropping can be identified early
and to be able to follow the short-term changes in cardiac
output during dynamic tests or therapeutic challenges.
Because such devices provide numerous important
hemodynamic variables, transpulmonary thermodilution
can be helpful in patients with shock refractory to ini-
tial treatment and especially in cases of associated
ARDS because of the assessment of extravascular lung
water.
Lithium dilution monitor
This system uses the lithium dilution method to calibrate
an arterial waveform analysis system. The technique has
been validated against pulmonary artery thermodilution
in humans [129], and agreement remains acceptable for
up to 4 h after calibration in critically ill patients [130].
The system needs a lithium bolus injection for its cali-
bration. The best calibrations are achieved, as is true for
any intermittent technique, by averaging more mea-
surements (i.e. 2–3 boluses) [131]. The device can be
used to measure and track cardiac output continuously in
patients with shock. In complex patients it has the
limitation of measuring fewer hemodynamic variables
than the PAC and the transpulmonary thermodilution
systems.
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Uncalibrated arterial pulse contour analysis monitors
Several devices provide real-time cardiac output mea-
surements by deriving the arterial pressure waveform
recorded from an artery catheter (radial or femoral). These
devices use proprietary algorithms that analyze the char-
acteristics of the arterial pressure waveform and use this
analysis, along with patient-specific demographic infor-
mation, to determine continuous cardiac output and PPV
and/or SVV. A theoretical advantage is that these devices
can be used with a radial artery catheter and do not need
calibration. However, the reliability of uncalibrated devi-
ces is still debated in the case of shock, particularly septic
shock [132–134]. More importantly, the fact that these
devices do not provide important variables, such as filling
pressures or transpulmonary thermodilution variables
(global end-diastolic volume, extravascular lung water,
etc.), represents a disadvantage compared with PAC or
transpulmonary thermodilution devices.
Recently developed systems use the pulse contour
analysis and the volume clamp method to monitor cardiac
output in real-time using an inflatable cuff wrapped around
a finger connected to a monitor. This non-invasive method
should be used during the perioperative period. However,
the value of this technique in the context of shock patients
and/or patients receiving vasopressors is questionable, as
confirmed by results from clinical studies which showed no
agreement with thermodilution cardiac output [135] or
velocity time integral [136] for estimating either absolute
values of cardiac output or for tracking changes in cardiac
output during therapy. In addition, patients with shock often
need an arterial catheter for their routine management.
Esophageal Doppler
The use of esophageal Doppler is aimed at monitoring
cardiac output by continuously measuring the blood flow
in the descending thoracic aorta. This method takes
advantage of the anatomical proximity of the thoracic
descending aorta and the esophagus. With this technique,
a flexible probe of small diameter is introduced into the
esophagus. The tip of the probe is equipped with a
Doppler transducer that records the velocity of red blood
cells passing into the descending thoracic aorta. To obtain
flow from velocity measurements, the diameter of the
descending aorta must be taken into account.
Most commercialized devices do not measure the aortic
diameter, but rather they estimate it from nomograms based
on the patient’s height, weight and age. With these devices,
the aortic diameter is thus considered to be a constant in a
particular patient. In patients with shock receiving resus-
citation, this assumption represents an important limitation
of using such devices because the aortic diameter depends
on the transmural aortic pressure, such that changes in
MAP result in changes in aortic diameter [137]. A practical
limitation of the technique is that the probe moves easily
into the esophagus when the patient is moving. Thus,
continuous monitoring of cardiac output requires frequent
replacement of the probe. Esophageal Doppler is more
suitable for the operating theater than for the ICU. Unfor-
tunately, esophageal Doppler can only provide blood flow
measurements, which limits its potential for hemodynamic
monitoring in the context of shock in comparison with
other monitoring devices, such as the PAC or transpul-
monary thermodilution.
Bioreactance
Bioreactance is a non-invasive technique used for moni-
toring cardiac output in real-time which uses skin surface
electrodes placed on the patient’s chest and neck that
apply a low-amplitude, high-frequency electrical current
which traverses the thorax. The signal is recorded by other
electrodes on the skin surface, with a time delay called a
phase shift. The underlying scientific rationale is that the
higher the cardiac stroke volume, the more significant
these phase shifts become. In critically ill patients,
including those with shock, a poor agreement between
thermodilution cardiac output and bioreactance cardiac
output has been reported in two studies [138, 139].
Monitoring cardiac function and cardiac output
• Echocardiography can be used for the sequential
evaluation of cardiac function in shock Statement of
fact.
• We do not recommend the routine use of the pulmonary
artery catheter for patients in shock. Recommendation.
Level 1; QoE high (A).
• We suggest PAC in patients with refractory shock and
RV dysfunction. Recommendation. Level 2; QoE low
(C).
• We suggest the use of transpulmonary thermodilution
or PAC in patients with severe shock especially in the
case of associated acute respiratory distress syndrome.
Recommendation. Level 2; QoE low (C).
• We recommend that less invasive devices are used,
instead of more invasive devices, only when they have
been validated in the context of patients with shock.
Best practice.
Monitoring the microcirculation
Several techniques are available to evaluate the micro-
circulation in critically ill patients. These show some
relation between altered microcirculation and poor out-
come. In experimental conditions, shock states have been
associated with a decrease in perfused capillary density
and an increase in the heterogeneity of microcirculatory
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perfusion, with non-perfused capillaries in close vicinity
to perfused capillaries [140].
The use of metabolic parameters for the assessment of
regional microcirculatory perfusion is promising. Tissue
CO2 represents the balance between local production and
removal; thus, a rising value likely reflects a decrease in
local blood flow rather than an increased local production of
CO2. When associated with arterial CO2, tissue CO2 allows
determination of the gradient or the PCO2 gap, which is
inversely related to the proportion of perfused capillaries
[141]. An occlusion test with near-infrared spectroscopy
may help to evaluate indirectly the dynamic response of the
microcirculation to an occlusion, even if the link between
vasoreactivity, microcirculation and tissue oxygenation is
still not clearly established. The evaluation of StO2 [tissue
(muscle) oxygen saturation] changes in response to a vas-
cular occlusion test provides two additional parameters: the
StO2-deoxygenation rate (DeOx), which has been related to
the local metabolic rate and local blood flow distribution,
and the StO2-reoxygenation rate (ReOx). In a population of
septic shock patients with restored MAP, decrements in
DeOx and ReOx were found to be associated with a longer
ICU stay, and impaired DeOx was associated with no
improvement in organ failures after 24 h [142]. The ReOx
rate seen on reperfusion is an measure of both the limb’s
oxygen content and the capacity to recruit arterioles and
venules (‘microvascular reserve’) [143].
Microvideoscopic techniques, such as orthogonal
polarization spectral and sidestream dark field imaging,
can directly evaluate microvascular networks covered by
a thin epithelium, such as the sublingual microcirculation.
They take into account the heterogeneity of microvascular
perfusion. The following parameters have been suggested
[144]: (1) a measure of vessel density (total or perfused
vessel density); (2) two indices of vascular perfusion
(proportion of perfused vessels and microcirculatory flow
index); (3) a flow heterogeneity index. These indices
evaluate how many vessels are perfused, the quality of the
flow and whether non-perfused areas are located next to
well-perfused areas. Using these techniques, microvas-
cular alterations, similar to those reported in experimental
conditions, have been observed in patients with septic
[145], cardiogenic [146], and hemorrhagic [147] shock.
One goal of the management of patients with shock
within the first hours after admission is to ensure adequate
tissue perfusion and cellular metabolism. In a prospective
observational study, early improvement in microvascular
perfusion in response to goal-directed therapy was asso-
ciated with an improvement in organ function [148].
These data strongly suggest that microcirculatory altera-
tions are implicated in the development of organ failure.
In a randomized, double-blind, crossover study by Her-
nandez et al. [149] in patients with pressor-dependent
septic shock and hyperlactatemia, increasing oxygen
delivery for 90 min by infusion of dobutamine did not
alter lactate clearance, regional flow (measured by gastric
tonometry PCO2) or microcirculatory flow (measured by
sublingual imaging
The use of microcirculatory markers of tissue perfu-
sion will require further large-scale studies to assess their
potential benefit in microcirculation-oriented or micro-
circulation-guided management and/or therapy of early
shock resuscitation. In summary, these techniques need
further exploration and are not presently recommended as
targets for resuscitation.
Monitoring microcirculation
• We suggest the techniques to assess regional circulation
or microcirculation for research purposes only. Rec-
ommendation. Level 2; QoE low (C).
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